What happened
Ahead of Menopause Awareness Month, the American Academy of Facial Plastic and Reconstructive Surgery released a finding from its 2025 member survey: 45 percent of facial plastic surgeons say more women now name menopause or perimenopause as the reason they are seeking treatment, up from 28 percent a year earlier. In the same survey, 66 percent report more requests for eyelid surgery from patients who want to look less tired, and most surgeons expect the average facelift patient to keep getting younger.
Women between 45 and 60 are the largest group in my facelift practice, and “since menopause” is a phrase I hear in most of those consultations. So this is an article about what the hormone actually does to a face, what it does not do, and which of those changes surgery can reach.
The common misconception
The misconception has two halves that patients often hold at the same time. The first is that the “menopause face” is a skin problem, so the answer is a cream, a laser or hormone therapy, and surgery is for later. The second is that once the face has changed, a facelift will put back everything the hormone took. Neither survives the anatomy. Menopause changes three layers at once: skin, fat and bone. Creams and hormones act on one of them, weakly. A facelift acts on a different one, strongly. Nothing acts on all three, and a consultation that does not separate them ends in disappointment in one direction or the other.
The clinical reality
Estrogen loss thins the skin at a measurable rate, and it is not a large one. The classic study measured skin collagen, skin thickness and bone mass in postmenopausal women and found all of them declining together at about 1 to 2 percent a year after the menopause, with the same connective-tissue loss driving both bone and skin. That is real: it is why the skin feels thinner and drier and why fine lines multiply. It is also slow. A face that changed dramatically in three years did not do it through 2 percent a year of collagen. It did it through volume and support, which is where menopause does its heavier work.
The bone moves, and the fat follows it down. Computed tomography of 120 faces across three age groups shows the eye socket widening, the cheekbone angle flattening, the opening around the nose enlarging and the jaw shortening with age in both sexes, and the drop in estrogen accelerates bone loss in women. When the scaffold retreats, the fat compartments that sat on it slide: the cheek deflates and the fold beside the nose deepens, the lower lid hollows, and the jowl forms where the jaw used to hold the tissue up. This is why women describe the change as sudden: the skin thinned for years, and the day the support gave way was the day the mirror changed. No cream reaches this layer.
Hormone therapy is a health decision, not a skin treatment, and the skin evidence says so. Patients ask me whether hormone replacement will save their face, and I give them the literature rather than an opinion outside my field. A 2025 review found most studies associating hormone therapy with better skin quality, but inconsistent, and concluded that no guideline supports prescribing it for skin alone. The largest randomized trial in recently menopausal women, 727 patients followed for four years, found no significant effect on skin wrinkling. Whether to take hormones is a conversation with a gynecologist about bones, heart, sleep and symptoms, not with me. What I tell patients is narrower: whatever it does for the skin, it does nothing for sagging, because sagging is bone and fat.
Healing after a facelift is not worse after menopause, whatever the laboratory says. In the laboratory, estrogen speeds skin repair and postmenopausal skin heals acute wounds more slowly; the effect is well documented. In the operating room it does not show up as complications. In a prospective database of 11,300 facelifts with a mean patient age of 59, the overall major complication rate was 1.8 percent and the independent risk factors were male sex, a body mass index above 25 and combined procedures. Age was not one of them. I see the same in my patients: a healthy 58-year-old heals a facelift as reliably as a healthy 48-year-old. What differs is not the healing but the tissue I am working with, thinner skin and a thinner, more delicate deep layer, which changes the plan, not the timeline.
Match the operation to the layer. If the complaint is texture, dryness and fine lines, that is skin, and the honest answers are sun protection, retinoids, mesotherapy and laser treatments, which we use in the clinic for exactly this, and none of which I sell as a substitute for the other layers. If the complaint is looking tired, that is usually the lower lid and the cheek beneath it, and eyelid surgery with volume restored to the cheek answers it; the survey’s 66 percent are describing this patient. If the complaint is the jowl, the fold and the neck, that is descent, and only a facelift that repositions the deep layer, not the skin alone, corrects it. Deflation is the fourth complaint and the one most often mistaken for sagging; it is treated with fat, which is a graft and not a filler, and in the postmenopausal face it usually belongs alongside the lift, not instead of it.
Timing is anatomy, not a birthday. The survey predicts younger facelift patients, and I understand why: a woman who watched her face change in the two years around menopause often wants it addressed at 52 rather than 62, and if the descent is there, there is no reason to wait for it to be worse. The reverse is also true. A 55-year-old with thin skin but a jaw that still holds does not need a facelift because a number came up; she needs the layer that actually changed treated. My article on surgery after 65 covers the other end of the same rule: the decision is made on the tissue and the health, at any age.
The practical takeaway for patients
Send photographs in daylight, front and both sides, and, if you have one, a photograph from before the change; five years back is ideal. Tell me when your periods stopped, whether you take hormone therapy, and what you notice most: the texture, the tiredness, the jowl or the hollows. Those four words point at four different layers.
Keep the hormone decision with your gynecologist. Bring me the answer, not the question; it changes the anesthetic plan, not whether I operate.
Expect a plan in layers. A good consultation for a menopausal face names what is skin, what is volume and what is descent, and tells you which of the three each treatment addresses. If a surgeon offers one operation for all three, ask which layer it is leaving out.
Judge the result at six months, not six weeks. Thinner skin swells and settles on the same schedule I described in the facelift swelling timeline; the calendar does not change with the hormone.
Honest limits
The collagen and bone studies are decades old and small, and the CT study describes aging in both sexes rather than menopause specifically; the estrogen effect on bone is inferred from what we know about bone elsewhere. The hormone-therapy trials measured wrinkling, not the deeper layers, so they cannot say whether hormones slow descent, only that no one has shown it. The facelift complication data come from a US insurance database of board-certified surgeons and do not travel to every setting. My own statement that menopause does not change healing is drawn from that database and from my patients, not from a trial designed to test it.
If your face has changed since menopause and you want to know which layer changed and what would address it, send unedited photographs and the year your periods stopped to +90 544 772 0772. The surgical team reviews them the same day.
Dr. Mustafa Aydınol is a plastic, reconstructive and aesthetic surgeon in Istanbul and a member of ISAPS.
Sources
- American Academy of Facial Plastic and Reconstructive Surgery. AAFPRS highlights growing conversation around menopause and facial aging: 45 percent of members report more patients citing menopause, up from 28 percent; 66 percent report rising eyelid procedures. Press release, 16 September 2026. Link
- American Academy of Facial Plastic and Reconstructive Surgery. AAFPRS reveals the trends defining facial plastic surgery: 2025 member survey, facelift patients expected to trend younger. Press release, February 2026. Link
- Brincat M, Kabalan S, Studd JW, et al. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman: decline of 1 to 2 percent per year. Obstet Gynecol, 1987. PubMed
- Shaw RB, Katzel EB, Koltz PF, et al. Aging of the facial skeleton: aesthetic implications and rejuvenation strategies, CT study of 120 subjects. Plast Reconstr Surg, 2011. DOI
- Viscomi B, Muniz M, Sattler S. Managing menopausal skin changes: a narrative review of skin quality changes and the actual role of hormone replacement therapy. J Cosmet Dermatol, 2025. DOI
- Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Randomized trial, 727 women, 4 years, no significant effect on skin wrinkling. Menopause, 2019. DOI
- Gilliver SC, Ashcroft GS. Sex steroids and cutaneous wound healing: the contrasting influences of estrogens and androgens. Climacteric, 2007. DOI
- Gupta V, Winocour J, Shi H, et al. Preoperative risk factors and complication rates in facelift: analysis of 11,300 patients, mean age 59, complication rate 1.8 percent, age not an independent risk factor. Aesthet Surg J, 2016. DOI
